Issue Date: August 29, 2011
Albany Molecular Lands NIH Contract
Albany Molecular Research Inc. has won a five-year contract from NIH and the National Institute of Neurological Disorders & Stroke to provide chemistry and other drug discovery technology in support of NINDS’s Medicinal Chemistry for Neurotherapeutics Program. AMRI will receive $10 million in funding for the first phase of the project, with the objective of delivering at least one Phase I clinical-trial candidate. The firm stands to receive as much as $43 million for the full contract. AMRI has collaborated with NINDS since 2005 on treating spinal muscular atrophy.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society